CraniUS Therapeutics focuses on developing innovative therapies for neurological disorders, leveraging advanced technologies to enhance patient outcomes. Their pipeline includes a range of products aimed at addressing conditions such as traumatic brain injury and neurodegenerative diseases. The company employs a multidisciplinary approach, integrating insights from neuroscience, pharmacology, and engineering to create effective treatment modalities that target the underlying mechanisms of these disorders.

The technologies utilized by CraniUS Therapeutics encompass novel drug delivery systems and biomaterials designed to optimize therapeutic efficacy and minimize side effects. Their research emphasizes the importance of precision medicine, utilizing data-driven methodologies to tailor treatments to individual patient needs. By combining cutting-edge scientific research with practical applications, CraniUS Therapeutics aims to revolutionize the management of neurological conditions and improve the quality of life for affected individuals.

United States

CraniUS' mission is to invent and engineer world-class technology to define the future of diagnostics and treatments for neurosurgical patients with brain disease.

CAUTION – The NeuroPASS device is an investigational device limited by Federal (or United States) law to investigational use and is not available for commercial distribution.

1700 union ave, baltimore, maryland, united states

CraniUS Therapeutics

Company Details